[Generation mechanisms and management strategies of adverse reactions to Bevacizumab during cancer treatment].
Ge
Fei-jiao
FJ
Xu
Jian-ming
JM
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use; D000068258:Bevacizumab; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D006973:Hypertension / Q000139:chemically induced* / Q000188:drug therapy; D007416:Intestinal Perforation / Q000139:chemically induced* / Q000601:surgery; D009369:Neoplasms / Q000188:drug therapy; D011507:Proteinuria / Q000139:chemically induced*; D013923:Thromboembolism / Q000139:chemically induced* / Q000188:drug therapy
D020533:Angiogenesis Inhibitors; D000806:Angiotensin-Converting Enzyme Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001241:Aspirin